Chemical formula: C₁₉H₂₁N₅O₄ Molecular mass: 383.401 g/mol PubChem compound: 4893
Prazosin causes a decrease in total peripheral vascular resistance through selective inhibition of postsynaptic alpha-1-adrenoreceptors in vascular smooth muscle. Prazosin has been found to successfully reduce the severity of the signs, symptoms, frequency and duration of attacks, in patients with Raynaud’s disease.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C02CA01 | Prazosin | C Cardiovascular system → C02 Antihypertensives → C02C Antiadrenergic agents, peripherally acting → C02CA Alpha-adrenoreceptor antagonists |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| HYPOVASE Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Prazosin is an active ingredient of these brands:
United States (US)
Australia (AU)
Brazil (BR)
Cyprus (CY)Finland (FI)
France (FR)
Hong Kong (HK)
Ireland (IE)
Japan (JP)
Lithuania (LT)
Mexico (MX)South Africa (ZA)
Spain (ES)
Tunisia (TN)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
